Cell and Gene Therapy CDMO Market to Reach $57.1 Billion by 2034

Industry
โดย GlobeNewswire·Read original
Summary · why it matters

The global cell and gene therapy CDMO market is projected to grow from $8.3 billion in 2025 to $57.1 billion by 2034, at a compound annual growth rate of approximately 24%, according to a report by DelveInsight. North America held the largest share in 2025, accounting for roughly 40% of the global market, driven by an expanding pipeline of cell and gene therapies and substantial investments in innovative technologies. Key companies in the market include Catalent, Minaris Advanced Therapies, SCTbio, Cellex Cell Professionals, Mycenax Biotech, MedTherapy Biotech, ENCELL, Nucelion Biotechnologies, Charles River Laboratories, Lonza Group, Thermo Fisher Scientific, and WuXi AppTec. Recent developments include Catalent expanding its agreement with Cartherics for iPSC-derived CAR-NK cell therapies in April 2026, and Lonza expanding its manufacturing agreement with Genetix Biotherapeutics for ZYNTEGLO in March 2026. The market growth is fueled by rising numbers of cell and gene therapy candidates, increasing outsourcing trends, and advancements in manufacturing technologies.

Impact on stocks 5

Biotech & Genomic Medicine▲ · 3 stocks
Mycenax Biotech
4726
▲ PositiveDemandrelevance

Listed as a key company in the growing CDMO market, with market growth driven by increasing therapy candidates.

Charles River Laboratories
CRL
▲ PositiveDemandrelevance

Mentioned as a key company in the growing cell and gene therapy CDMO market, which is projected to grow at 24% CAGR.

Health Care▲ · 1 stocks
Lonza Group AG
LONN
▲ PositiveDemandrelevance

Mentioned as a key company and noted for expanding manufacturing agreement for ZYNTEGLO, indicating demand growth.

Others▲ · 1 stocks
WuXi AppTec Co Ltd
603259
▲ PositiveDemandrelevance

Named as a key company in the cell and gene therapy CDMO market, which is forecast to grow significantly.

Theme Impact 1

Off-coverage companies 9

Catalent, Inc.Private▲ Positive
Demandrelevance

Catalent is a key CDMO in the growing cell and gene therapy market, with a recent expansion agreement with Cartherics.

CarthericsPrivate▲ Positive
Demandrelevance

Catalent expanded its agreement with Cartherics for iPSC-derived CAR-NK cell therapies, indicating growing demand for its CDMO services.

MedTherapy BiotechPrivate▲ Positive
Demandrelevance

Market growth forecast indicates rising demand for CDMO services, benefiting MedTherapy Biotech as a listed key company.

Minaris Advanced TherapiesPrivate▲ Positive
Demandrelevance

Market growth forecast indicates rising demand for CDMO services, benefiting Minaris Advanced Therapies as a listed key company.

Nucelion BiotechnologiesPrivate▲ Positive
Demandrelevance

Market growth forecast indicates rising demand for CDMO services, benefiting Nucelion Biotechnologies as a listed key company.

SCTbioPrivate▲ Positive
Demandrelevance

Market growth forecast indicates rising demand for CDMO services, benefiting SCTbio as a listed key company.

bluebird bioPrivate± Mixed
relevance

Cellex Cell ProfessionalsPrivate± Mixed
relevance

ENCellPrivate± Mixed
relevance

Related news

Avantor Expands RIM Single-Use Bioprocessing Portfolio Across APAC

Avantor has expanded the availability of its RIM single-use bioprocessing portfolio across the Asia Pacific region, strengthening its presence in a key biopharma manufacturing market. The portfolio includes single-use consumables such as bioprocessing bags, assemblies, tubing and components, plus mixing and storage hardware, and is manufactured at Avantor's Changzhou, China facility, the company's first single-use production site in APAC. That 2,600-square-meter plant operates under ISO 9001:2015 certification and Good Manufacturing Practice standards, and RIM products are available exclusively to APAC customers. The move aligns with management's broader Revival strategy, and in the second quarter of 2026 the Bioscience & Medtech Products segment posted double-digit order growth and a book-to-bill ratio of 1.1x, with management expecting the segment to return to organic growth in the second half of 2026. Avantor currently has a market capitalization of $10.56 billion, and its shares have gained 38.4% year to date versus 3.4% growth for the industry and a 10.1% rise in the S&P 500.
AVTR ▲
Biotech & Genomic Medicine
Zacks Investment Research·16hRead more →
▲

Andelyn Begins Commercial Manufacturing of Ultragenyx's FDA-Approved FAYUVI Gene Therapy

Andelyn Biosciences announced it is now manufacturing FAYUVI, Ultragenyx Pharmaceutical Inc.'s FDA-approved gene therapy for Sanfilippo syndrome type A, also known as mucopolysaccharidosis type IIIA, for commercial supply at its Columbus, Ohio facility. The move follows the U.S. Food and Drug Administration's approval of FAYUVI, making it the first FDA-approved gene therapy manufactured using the Andelyn AAV Curator Platform process. Sanfilippo syndrome type A is a rare, fatal lysosomal storage disease that primarily affects the central nervous system and is marked by rapid neurodegeneration beginning in early childhood; it is estimated to affect 3,000 to 5,000 patients worldwide, with a median life expectancy of 15 years. Andelyn Chief Executive Officer Wade Macedone said the company is proud to manufacture an FDA-approved gene therapy for commercial use using an AAV Curator Platform process, calling the milestone a reflection of the purpose behind Andelyn's founding. Andelyn, a full-service FDA-inspected cell and gene therapy commercial CDMO with more than 20 years of experience, has produced clinical and commercial material for more than 500 cGMP batches and 85 global clinical trials.
RARE ▲
Biotech & Genomic Medicine ▲
PR Newswire·18hRead more →
▲2

Charles River Laboratories Launches Rapid Cell Banking Platform With 40% Faster Production

Charles River Laboratories International unveiled new rapid cell banking and release programs that use advanced sequencing and in vitro tools to shorten biologics and advanced therapy cell bank lead times for biopharma clients. The platform cuts cell bank production time by 40% and combines rapid microbiological methods with NGS characterization, including the iDTECT NGS platform, to support regulatory readiness. Charles River says the approach reduces reliance on animal testing by incorporating alternative in vitro methods aligned with the 3Rs framework. The company, a US life sciences group with a market cap of about $13.1b, positions the offering for time-sensitive programs where delays are costly. Investors will watch for booked projects using the iDTECT NGS platform, client mix in advanced therapies, and whether the services appear in updated segment revenue breakdowns.
CRL
Biotech & Genomic Medicine ▲
Simply Wall St·21hRead more →
© 2026 MarketDXNews